AA
ALGS icon

AlphaMark Advisors’s Aligos Therapeutics ALGS Stock Holding History

AlphaMark Advisors’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$44K Buy
1,100
+1,000
+1,000% +$19.3K 0.02% 253
2024
Q3 		$1K Buy
+100
New +$1.24K ﹤0.01% 641

Other funds holding ALGS

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
TI
Trexquant Investment Stamford, Connecticut $13.9B AUM 31.98% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

AlphaMark Advisors's ALGS Position: Q4 2024 in Review

AlphaMark Advisors increased its Aligos Therapeutics (ALGS) stake by 1,000% in Q4 2024, buying an estimated $19.3K and bringing the position to 1,100 shares worth $44K. The position accounts for 0.02% of the portfolio, ranked #253.

AlphaMark Advisors first reported a position in ALGS in Q3 2024 and has held it in 2 quarters since. 34 funds tracked by Wall St. Rank hold ALGS as of Q4 2024.

  • AlphaMark Advisors held 1,100 shares of Aligos Therapeutics worth $44K as of Q4 2024.
  • AlphaMark Advisors bought 1,000 Aligos Therapeutics shares in Q4 2024, an estimated $19.3K.
  • Aligos Therapeutics made up 0.02% of AlphaMark Advisors's portfolio in Q4 2024, its #253 holding.
  • AlphaMark Advisors first reported a position in Aligos Therapeutics in Q3 2024 and has held it in 2 quarters since.
  • 34 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q4 2024.

Based on AlphaMark Advisors's 13F filing for Q4 2024, filed 21 Jan 2025.